---
source_pdf: "https://drive.google.com/file/d/16CwgKIZVPkmfFnFpmAB6yVnVDC6wKvTl/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "H1, Series B Deck .pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/16CwgKIZVPkmfFnFpmAB6yVnVDC6wKvTl/view)

## Slide 1: Creating a healthier future

**Header:** H1INSIGHTS.COM

**Logo:** H1

**Main Title:**
Creating a healthier future

*(Visuals: Background includes various interconnected card-like diagrams representing profiles or data points, suggesting a network or ecosystem. Some are connected by lines, forming a distributed network structure.)*

---

## Slide 2: Founders

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 2

### Ariel Katz
*   CEO, Co-Founder
*   Prior exit for Gates Foundation.
*   2-time founder.

*(Associated Logos/Experience: BILL & MELINDA GATES foundation, RESEARCH: CONNECTION, Y Combinator)*

### Ian Sax
*   Co-Founder
*   Chief Data Officer for global data platforms.
*   2-time founder.

*(Associated Logos/Experience: IPREO By IHS Markit, THOMSON REUTERS, S&P Capital IQ, Y Combinator)*

---

## Slide 3: Management Team

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential

**Title:** Management Team

*   **Marc Eigner**
    *   Chief Commercial
*   **Joey Litman**
    *   General Counsel
*   **Lisa Hou**
    *   VP Finance
*   **Dave Frau**
    *   VP Engineering
*   **Dave Shapiro**
    *   VP Product
*   **Stacey Rivkin**
    *   VP Solutions
*   **Ben Carmel**
    *   VP Sales
*   **Kristina Geier**
    *   VP Customer
*   **Peter Sparks**
    *   VP Data Eng.
*   **Will Hickson**
    *   VP of Data
*   **Devin Basinger**
    *   VP Innovation

---

## Slide 4: Mission Statement

**Header:** H1INSIGHTS.COM

**Logo:** H1

**Main Statement:**
H1 builds a healthier future by connecting parties in the healthcare ecosystem.

*(Visuals: Similar to the title slide, showing interconnected card-like diagrams with icons representing different entities like people, institutions, drugs, NIH, etc., forming a network.)*

---

## Slide 5: Customers

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 5

**Customer Metrics:**
*   **12** of top 20 Pharma companies signed
*   **52** Total customers
*   **$152,000** ACV

**Customer Logos:**
*   MERCK
*   abbvie
*   GILEAD
*   NOVARTIS
*   Janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson
*   Pfizer
*   ROIVANT SCIENCES
*   SANOFI
*   AstraZeneca
*   IPSEN
*   Abbott
*   Baxter
*   Lilly
*   Alkermes
*   Allergan

---

## Slide 6: ARR Growth

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 6

**Title:** ARR Growth

**ARR ($ Millions) Data:**

| Year | ARR ($ Millions) | Growth Factor |
| :--- | :--------------- | :------------ |
| 2018 | $810k            |               |
| 2019 | $2.2M            | 2.7X          |
| 2020 | $7M              | 3.1X          |
| 2021 | $18.5M           | 2.7X          |

*(Visuals: Bar chart showing significant year-over-year ARR growth.)*

---

## Slide 7: Key Financial Metrics

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 7

**Title:** Key Financial Metrics

| Metric             | 2020            | 2021 (Forecast) |
| :----------------- | :-------------- | :-------------- |
| **CAC Payback Period** |                 |                 |
| New Customer       | $45k            | $82k            |
|                    | 7.6 months      | 12.5 months     |
| Expansion          | $25k            | $72k            |
|                    | 3.6 months      | 5 months        |
| **Gross Margin**   | 70%             | 67%             |
| **Net Retention**  | 156%            | 150%            |

---

## Slide 8: KOL Solutions - Competitive Positioning

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 8

**Title:** KOL Solutions - Competitive Positioning

*(Visual: A 2x2 matrix with "Regional Coverage" on the X-axis (left to right) and "KOL Data Depth" on the Y-axis (bottom to top).)*

**Companies positioned in the matrix:**
*   DEFINITIVE HEALTHCARE (High Depth, Low Regional Coverage)
*   komodohealth (Low Depth, Low Regional Coverage)
*   Veeva (Mid Depth, Low Regional Coverage)
*   MONOCL (Low Depth, High Regional Coverage)
*   H1 (High Depth, High Regional Coverage)

**Feature Comparison Table:**

| Feature                      | H1 | Veeva | MONOCL | komodohealth | DEFINITIVE HEALTHCARE |
| :--------------------------- | :- | :---- | :----- | :----------- | :-------------------- |
| Covers every TA              | X  | X     |        |              |                       |
| Global coverage              | X  |       |        |              |                       |
| Claims coverage              | X  | X     | X      | X            |                       |
| Country-specific sources     | X  | X     | X      |              |                       |
| Social media coverage        | X  | X     | X      |              |                       |
| Multi-language support       | X  |       |        |              |                       |
| Every HCP in TA included     | X  | X     |        | X            |                       |
| Accurate affiliation information | X  | X     |        | X            |                       |

---

## Slide 9: Current & Future Offerings

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 9

**Title:** Current & Future Offerings

### Today
*   KOL solutions enhance how Pharma connects with HCPs.
    *   *(Visual: Screenshot of "Industry to HCPs" product interface showing "Saved Lists," "Citations," "Social Media," and a professional profile. Features like "View Contact Details" are visible.)*

### 2021-2022
*   H1 will grow by connecting hospitals and HCPs.
    *   **Industry to HCPs**
        *   *(Visual: Screenshot of a product interface showing "Payor Type" and a map with data points, suggesting geographical insights.)*
    *   **Hospitals to HCPs**
        *   *(Visual: Diagram showing a network of interconnected entities, likely representing hospitals and HCPs.)*
    *   **HCPs to HCPs**
        *   *(Visual: Diagram showing an even more granular network of individuals, representing HCPs connecting with other HCPs.)*

---

## Slide 10: H1 Growth & Product Expansion

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1

**Title:** H1 Growth & Product Expansion

| Product/Market        | 2019 | 2020    | 2021    | 2022 Target | Serviceable TAM |
| :-------------------- | :--- | :------ | :------ | :---------- | :-------------- |
| KOL (Medical)         | MVP  | Growth  | Scale   | $25M        | $500M           |
| KOL (Commercial)      |      | Build   | MVP     | Growth      | $5M             | $1B+            |
| Industry to Hospitals |      |         | Build   | MVP         | Growth          | $3M             | $750M+          |
| Hospitals to HCPs     |      |         | Build   | MVP         | Growth          | $3M             | $350M           |
| HCP to HCP            |      |         | Build   | MVP         | Growth          | 20K users       | 14M users       |
|                       |      |         |         |             |                 |
| **Total ARR**         |      |         |         | **$35M**    | **$2.6B**       |

**Page Number:** 10

---

## Slide 11: Raising $25M

**Header:** H1INSIGHTS.COM

**Logo:** H1

**Main Message:**
Series B
Raising $25M

*(Visuals: Similar network diagram background with icons. "CT" is also visible as an icon.)*

---

## Slide 12: Thank you.

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1 - Confidential

**Logo:** H1

**Message:**
Thank you.

**Contact Information:**
Ariel Katz
Founder, CEO
Ariel.katz@h1insights.com

---

## Slide 13: Product Intro: KOL Identification (Medical Affairs)

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 13

**Title:** Product Intro: KOL Identification (Medical Affairs)

**Description:**
Access data on publications, clinical trials, payments, and more to search and identify Key Opinion Leaders.

**Customer:**
Pharma, Medical Affairs

*(Visuals: Screenshot of the H1 platform interface for "KOL Identification".)*

**Top Metrics from Search Results:**

| Category       | Count        |
| :------------- | :----------- |
| KOLS           | 32,433       |
| Institutions   | 1,289        |
| Publications   | 11 million   |
| Clinical Trials | 102,676      |
| Congresses     | 150          |
| Congress Sessions | 17,346       |
| Grants         | $38.4 billion |
| Payments       | $418 million |

**Profile Overview for Donald Y M Leung, PhD, MD:**

*   **Affiliations:**
    *   National Jewish Health, Denver, Colorado, United States (Active)
    *   NPI: 1215012950
    *   **Specialty:** Allergy & Immunology, Pediatrics - Pediatric Allergy/Immunology

**Summary of Associated Assets:**

| Asset Category | Total | Details                    |
| :------------- | :---- | :------------------------- |
| PUBLICATIONS   | 969   | Citations: 48.6k           |
|                |       | h-index: 196               |
|                |       | Social Media Mentions: 378 |
| CLINICAL TRIALS | 24    | Completed: 19              |
|                |       | Terminated: 19             |
|                |       | In-progress: 5             |
| CONGRESSES     | 21    |                            |
| OPEN PAYMENTS  | 706.6k | Avg. per year: 141.3k      |
| CLAIMS         |       | Diagnoses: 5               |
|                |       | Procedures: 5              |

---

## Slide 14: Product Intro: KOL Identification (Commercial)

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 14

**Title:** Product Intro: KOL Identification (Commercial)

**Description:**
Access data and insights from medical claims for more than 200M patients to identify clinical influencers, referral patterns, and more.

**Customer:**
Pharma, Commercial & Marketing

*(Visuals: Screenshot of the H1 platform interface for "KOL Identification (Commercial)".)*

**Referred Organizations (Top referrals from Ravindra):**

*   **Pie Chart Distribution:**
    *   O'Connor Hospital: 34%
    *   Kaiser Permanente - SF: 20%
    *   St. Rose Hospital: 12%
    *   Alameda Health System: 6%

**Referrals From Ravindra (Detailed Table):**

| Recipient          | Recipient's Speciality          | Service Line           | Referrals from Ravindra | % of Ravindra's Referrals Sent | Referrals from Others |
| :----------------- | :------------------------------ | :--------------------- | :---------------------- | :----------------------------- | :-------------------- |
| Barbara Haley      | Hematology & Oncology           | All                    | 464                     | 30%                            | 2,812                 |
| UT Southwestern University Hospital, Austin, Texas |                         | Cardiovascular disease | 231                     | 11%                            | 712                   |
|                    |                                 | Pulmonary disease      | 230                     | 10%                            | 800                   |
|                    |                                 | Cardiac Arrest         | 229                     | 9%                             | 234                   |
| Alex Jones         | Hematology & Oncology, Cardiology | All                    | 363                     | 20%                            | 50,000                |
| UT Southwestern University Hospital, Austin, Texas |                         | Cardiovascular disease | 231                     | 10%                            | 123                   |
|                    |                                 | Pulmonary disease      | 100                     | 5%                             | 800                   |
| Joe Schmoe         | Hematology & Oncology, Cardiology | All                    | 262                     | 10%                            | 2,812                 |
| UT Southwestern University Hospital, Austin, Texas |                         | Cardiovascular disease | 131                     | 5%                             | 456                   |
|                    |                                 | Pulmonary disease      | 130                     | 3%                             | 123                   |

**Private Insurance Plans (from a pie chart and table):**

*   **Pie Chart Distribution:**
    *   Medicaid: 48%
    *   Private: 37%
    *   Medicare: 15%

**Private Insurance Plans (Table):**

| NAME                  | % OF PATIENTS |
| :-------------------- | :------------ |
| SFCUT                 | 25.1%         |
| SF Community Plan     | 22.7%         |
| Steward Healthcare    | 5.1%          |
| Care 1st Access       | 4.7%          |
| Aetna PPO             | 3.5%          |
| BCBS HMO              | 2.6%          |
| Anthem Blue Cross     | 2.3%          |

---

## Slide 15: Product Intro: Industry to Hospitals

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 15

**Title:** Product Intro: Industry to Hospitals

**Description:**
Use extensively curated clinical trial site data to understand the clinical landscape. Combine with 8 Billion medical claims to provide a powerful planning resource for clinical trials.

**Customer:**
Pharma, Clinical Ops

*(Visuals: Screenshot of the H1 platform interface showing diagnosis codes by patient volume and a map of patient volume based on zip codes.)*

**EXAMPLE: VOLUME INFORMATION IN MELANOMA (1 OF 4)**

**DIAGNOSIS CODES BY PATIENT VOLUME**

| DX CODE | DESCRIPTION                                          | # CLAIMS  | # PATIENTS |
| :------ | :--------------------------------------------------- | :-------- | :--------- |
| I72.9   | Melanoma of skin, site unspecified                   | 483,609   | 138,863    |
| V10.82  | Personal history of malignant melanoma of skin       | 289,057   | 112,046    |
| I72.5   | Malignant melanoma of skin of trunk, except scrotum  | 239,814   | 83,871     |
| I72.6   | Malignant melanoma of skin of upper limb, including shoulder | 166,830   | 59,970     |
| I72.7   | Malignant melanoma of skin of lower limb, including hip | 145,242   | 43,914     |

**EXAMPLE: MELANOMA (2 OF 4)**

**Mapping of patient volume based on patient zip codes within medical claims.**

*   Zip codes will be stack-ranked to identify the most promising patient populations based on diagnosis records.
*   Zip codes will be identified based on a combination of relevant diagnosis counts, along with other target criteria as outlined by client.

*(Visual: A choropleth map of the United States showing patient volume for melanoma, color-coded by density.)*

---

## Slide 16: Product Intro: Hospitals to HCPs

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 16

**Title:** Product Intro: Hospitals to HCPs

**Description:**
View market share of patient referrals by region and service line. Focus physician liaison efforts to increase profitability by finding ideal patient referrals.

**Customer:**
Hospitals, Marketing & BD

*(Visuals: Screenshot of the H1 platform interface showing "Referred Organizations" and "Referrals From Ravindra" sections.)*

**Referred Organizations (Top referrals from Ravindra distribution):**

*   **Pie Chart Distribution:**
    *   Barbara Haley: 30%
    *   Alex Jones: 25%
    *   Joe Schmoe: 20%
    *   Alex Jones II: 15%
    *   Others: 8%

**Referrals From Ravindra (Detailed Table):**

| Recipient          | Recipient's Speciality          | Service Line           | Referrals from Ravindra | % of Ravindra's Referrals Sent | Referrals from Others |
| :----------------- | :------------------------------ | :--------------------- | :---------------------- | :----------------------------- | :-------------------- |
| Barbara Haley      | Hematology & Oncology           | All                    | 464                     | 30%                            | 2,812                 |
| UT Southwestern University Hospital, Austin, Texas |                         | Cardiovascular disease | 231                     | 11%                            | 712                   |
|                    |                                 | Pulmonary disease      | 230                     | 10%                            | 800                   |
|                    |                                 | Cardiac Arrest         | 229                     | 9%                             | 234                   |
| Alex Jones         | Hematology & Oncology, Cardiology | All                    | 363                     | 20%                            | 50,000                |
| UT Southwestern University Hospital, Austin, Texas |                         | Cardiovascular disease | 231                     | 10%                            | 123                   |
|                    |                                 | Pulmonary disease      | 100                     | 5%                             | 800                   |
| Joe Schmoe         | Hematology & Oncology, Cardiology | All                    | 262                     | 10%                            | 2,812                 |
| UT Southwestern University Hospital, Austin, Texas |                         | Cardiovascular disease | 131                     | 5%                             | 456                   |
|                    |                                 | Pulmonary disease      | 130                     | 3%                             | 123                   |

---

## Slide 17: Product Intro: HCP to HCPs

**Header:** H1INSIGHTS.COM
**Copyright:** Copyright © 2020 H1-Confidential
**Page Number:** 17

**Title:** Product Intro: HCP to HCPs

**Description:**
Doctors, medical students, and HCPs can claim their personal H1 profile. Follow researchers & peers, navigate professional networks, and match with funding opportunities.

**Customer:**
Pharma, Hospitals, HCPs

*(Visuals: Screenshot of the H1 platform interface showing a profile for "Josep M. Llovet".)*

**Profile Overview for Josep M. Llovet, MD:**

*   **Project:** Global Oncology
*   **Don Pinkus** (Likely a user/account name)
*   **Title:** MD, Hematology/oncology, Internal Medicine
*   **NPI:** 1316020290
*   **AFFILIATIONS:**
    *   Society of Hematologic Oncology, Woodlands, Texas, United States (Active)
        *   hkantarjian@hemaonco.org
        *   (515) 331-7026
    *   University of Texas at Austin, Austin, Texas, United States (Not available)
    *   The University of Texas MD Anderson Center, Houston, Texas, United States (Active)
        *   hkantarjian@mdanderson.org
        *   (713) 792-7026

**Summary of Associated Assets:**

| Asset Category | Total | Details                    |
| :------------- | :---- | :------------------------- |
| PUBLICATIONS   | 414   | Citations: 57.9k           |
|                |       | h-index: 151               |
|                |       | Social Media Mentions: 628 |
| CLINICAL TRIALS | 7     | Completed: 7               |
|                |       | Terminated: 7              |
| CONGRESSES     | 5     |                            |

**MOST RECENT ACTIVITIES:**

*   **PUBLICATION:** Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.
    *   **Authors:** Stephen Chan, Josep Llovet, Peter Galle, Masatoshi Kudo, Andrew Zhu, Friedrich Foerster
    *   **PMID:** 31436873
    *   **Date Published:** Nov 2019
    *   **Citations:** 1
    *   **Social Media Mentions:** 23
    *   **Journal:** Liver international: official journal of the... See More